Ebola Vaccines Elicit Immune Responses in Liberian Adults — Physician’s First Watch

Medical News |
October 12, 2017

Ebola Vaccines Elicit Immune Responses in Liberian Adults

By Amy Orciari Herman

Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM

Two investigational vaccines against Ebola virus safely provoked immune responses in a large group of Liberian adults, according to an industry-supported, phase 2 trial in the New England Journal of Medicine.

Some 1500 nonpregnant adults without a history of Ebola disease were randomized to receive injections of the chimpanzee adenovirus 3–based vaccine (ChAd3-EBO-Z), the recombinant vesicular stomatitis virus–based vaccine (rVSVΔG-ZEBOV-GP), or matching placebo. By 1 month, an antibody response was observed in 71%–84% of active-vaccine recipients, versus 3% of placebo recipients. Antibody responses were largely maintained at 1 year.

Serious adverse events did not differ across the groups.

Dr. Carlos del Rio of NEJM Journal Watch Infectious Diseases commented, "These findings suggest that we have potentially two highly immunogenic Ebola vaccines that could be deployed when the next outbreak occurs."

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.